All PlansCoverageLow impact
Germline Genetic Testing for Familial Cutaneous Malignant Melanoma (CDKN2A, CDK4)
Blue Cross & Blue Shield of Mississippi·MS · Dermatology, Oncology, Family Medicine +1 more·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has updated their policy on germline genetic testing for familial cutaneous malignant melanoma (CDKN2A, CDK4) genes, maintaining that this testing is considered investigational and not covered. The policy provides updated clinical background information but does not change coverage status.
Action Required
Billing team should verify that genetic testing claims for CDKN2A and CDK4 genes (CPT 81404) are not submitted to BCBS Mississippi as they remain non-covered investigational services. Ensure providers are aware that these tests will be denied if billed to this payer.